Forefront Analytics
JSPR icon

Forefront Analytics’s Jasper Therapeutics JSPR Stock Holding History

Forefront Analytics’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-369
Closed -$77.6K – 69
2023
Q3 		$77.6K Buy
369
+138
+60% +$50.5K 0.04% 57
2023
Q2 		$95K Buy
231
+130
+129% +$57.9K 0.05% 56
2023
Q1 		$54.8K Sell
101
-279
-73% -$155K 0.03% 71
2022
Q4 		$55.1K Sell
380
-19
-5% -$3.82K 0.03% 68
2022
Q3 		$94K Buy
399
+284
+247% +$156K 0.05% 53
2022
Q2 		$69K Buy
115
+6
+6% +$5.13K 0.03% 57
2022
Q1 		$118K Buy
+109
New +$147K 0.04% 60

Other funds holding JSPR

Velan Capital Investment Management
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Qiming U.S. Ventures Management
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Sphera Funds Management
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Ally Bridge Group
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Forefront Analytics's JSPR Position: Q4 2023 in Review

Forefront Analytics sold out of Jasper Therapeutics (JSPR) in Q4 2023, closing a stake of 369 shares — an estimated $77.6K sold.

Forefront Analytics first reported a position in JSPR in Q1 2022 and held it in 7 quarters. The position peaked at $118K in Q1 2022. 40 funds tracked by Wall St. Rank hold JSPR as of Q4 2023.

  • Forefront Analytics reported no remaining Jasper Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Forefront Analytics sold 369 Jasper Therapeutics shares in Q4 2023, an estimated $77.6K.
  • Forefront Analytics first reported a position in Jasper Therapeutics in Q1 2022 and held it in 7 quarters.
  • Forefront Analytics's Jasper Therapeutics position peaked at $118K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2023.

Based on Forefront Analytics's 13F filing for Q4 2023, filed 14 Feb 2024.